PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

COVID-19 is rising in prevalence in many states nationally following the July 4 holiday week, but the role of the main therapy to treat it — the antiviral drug Paxlovid — is less clear. Research ...

A hormone-free pill, known as YCT-529, that temporarily stops sperm production by blocking a vitamin A metabolite, has concluded its first safety trial in humans, getting a step closer to increasing ...

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...

The second healthcare sector IPCEI – approving up to €403 million of State aid by five Member States, including France, ...

The new shots won’t be available until the fall, and are expected to be approved only for adults 65 and up and kids and ...

Minnesota health advocates rely on deep listening, cultural connections to work through vaccine mistrust in marginalized ...

Current approaches in bioengineering are synthesized and methods for their implementation are suggested for the induction and modulation of trained immunity in the treatment of human diseases.